QR Code

Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia

Abstract Background Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms of such benefit have not been fully understood, and whether empagliflozin can be...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Elena Fortin, Magnus Lundin, Linda Mellbin, Anna Norhammar, Per Näsman, Stina Smetana, Peder Sörensson, Ele Ferrannini, Lars Rydén, Giulia Ferrannini
Hōputu: Artigo
Reo:Inglês
I whakaputaina: BMC 2023-08-01
Rangatū:Cardiovascular Diabetology
Ngā marau:
Empagliflozin
Insulin resistance
Myocardial infarction
Dysglycaemia
Cardiac magnetic resonance
Urunga tuihono:https://doi.org/10.1186/s12933-023-01950-0
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite